hemoadsorption with cytosorb
Conditions
Interventions
Group 1: intensive care patients with hemoadsorption therapy (CytoSorb® 300 ml, CytoSorbents Europe GmbH, Berlin, Germany)
observation study, no control group
Sponsors
Charité-Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: intensive-care patients in the department of anesthesiology and intensive care CBF Berlin Necessity of a veno-venous renal replacement therapie mit use of Cytosorb-filter according to local SOP and international recommendations
Exclusion criteria
Exclusion criteria: age 80 years pregnant or possible pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluation of plasma levels of anti-infectiv agents (before and after cytosorb) | — |
Secondary
| Measure | Time frame |
|---|---|
| -length of stay on ICU and in hospital - evaluation of plasma levels of anti-infectiv agents (before and after filter of dialysis) - evaluation of SOFA, TISS, SAPS2 and Apache2-Scores during the stay - evaluation of lab results (lactat, leucocytes, CRP, base excess, hemoglobin, kreatinin in standard blood samplings - length of surgical procedures, length of anesthesia, intraoperative blood loss - length of ventilation - mode of ventilation - length of dialyses - diuresis - use of catecholamines during anesthesia und during ICU-stay - use of blood products and volume - organ complications - vital signs and their indices (blood pressure, heart frequence, cardiac index, stroke volume, SVV, SVI, PPV) - central venous pressure and saturation | — |
Countries
Germany
Contacts
Public ContactStefan Angermair
Charité-Universitätsmedizin Berlin
Outcome results
None listed